English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/102109
logo share SHARE   Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

GSK-3 inhibitors as new leads for Parkinson's disease pharmacotherapy

AuthorsSusín, Cristina ; Morales-García, José A. ; Gil, Carmen ; Martínez, Ana ; Pérez Castillo, Ana
Issue Date2011
CitationAP/PD 2011
AbstractParkinson's disease (PD) is a devastating neurodegenerative disorder characterized by degeneration of the nigrostriatal dopaminergic pathway. As the current therapies only lead to temporarily limited improvement, and have side effects, new approaches to treat Parkinson disease need to be developed. To discover new leads for further pharmaceutical development we have screened our in-house chemical library on a well-established cellular model of PD. In depth in vitro studies to look for the mechanism of action of the selected compounds are pursued. From the screening of more than 400 chemically diverse molecules, we have selected 15 compounds for more in deep analysis. After different enzymatic assays we found that SC001 is a GSK-3 inhibitor with an IC50=3,38 M. Based on this, we have evaluated other chemically different GSK-3 inhibitors, many of them synthesized in our laboratory [1, 2], as potential neuroprotective agents for PD. Our results show that SC001 and other GSK-3 inhibitors have neuroprotective and anti-inflammatory effects in vitro. Furthermore, SC001 protected dopa-minergic neurons and reduced microglia activation in an in vivo model of PD.
DescriptionPóster presentado a la "10th International Conference on Alzheimer's & Parkinson's Diseases" celebrada del 9 al 13 de marzo de 2011 en Barcelona (España).
Appears in Collections:(IIBM) Comunicaciones congresos
(IQM) Comunicaciones congresos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.